Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Aducanumab and the Business of Alzheimer Disease; Implicit Light Sensitivity in Migraine

Aducanumab and the Business of Alzheimer Disease; Implicit Light Sensitivity in Migraine

FromNeurology® Podcast


Aducanumab and the Business of Alzheimer Disease; Implicit Light Sensitivity in Migraine

FromNeurology® Podcast

ratings:
Length:
21 minutes
Released:
Oct 25, 2021
Format:
Podcast episode

Description

In the first part of the podcast, Dr. Jason Crowell discusses the business of Alzheimer disease and how to approach teaching patients about aducanumab with Dr. Jason Karlawish. In the second segment, Dr. Jennifer Bickel talks with Dr. Eric Kaiser about the contribution of melanopsin and cone signals to light-induced reflexive eye closure in migraine.
Released:
Oct 25, 2021
Format:
Podcast episode

Titles in the series (100)

The Neurology podcast is introduced by Editor-in-Chief Robert A. Gross, MD, PhD, who discusses several highlighted articles in the current issue of Neurology®. The podcast regularly features content from Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation. Opening segments include interviews with authors who summarize a current article and discuss the main findings and clinical implications for neurologists. It concludes with the Lesson of the Week, a short segment on a topic such as a laboratory technique, statistical methods, or historical neurology. Regular features also include Delayed Recall, ePearls, and What’s Trending. Podcast listeners can earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions related to Neurology content in the online Podcast Quiz. (Delayed recall, Neurology® Clinical Practice, Neurology® Genetics, and Neurology® Neuroimmunology & Neuroinflammation contents are excluded from the CME program). The exams are posted weekly on Wednesday.